Crossref
EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer
AME Clinical Trials Review · 2026-06 · 4 · 25-25
DOI: 10.21037/actr-25-109 ↗Kurz gefasst
Fachartikel in der Zeitschrift AME Clinical Trials Review, 2026-06. Verfasst von Mali Barbi und 2 weiteren Autor:innen.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Barbi, M., Bhana, D., & John, V. S. (2026). EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer. AME Clinical Trials Review, 4, 25-25. https://doi.org/10.21037/actr-25-109
Vancouver
Barbi M, Bhana D, John VS. EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer. AME Clinical Trials Review. 2026;4:25-25. doi:10.21037/actr-25-109
BibTeX
@article{Barbi2026,
author = {Barbi, Mali and Bhana, Divya and John, Veena S.},
title = {EPIK-O and beyond: PI3Kα inhibition plus PARP blockade in platinum-resistant BRCA-wildtype ovarian cancer},
journal = {AME Clinical Trials Review},
year = {2026},
volume = {4},
pages = {25--25},
doi = {10.21037/actr-25-109}
}
EUVIMED